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Abstract
Background: To date, the clinical presentation and prognosis of mixed ductal/lobular mammary carcinomas has not 
been well studied, and little is known about the outcome of this entity. Thus, best management practices remain 
undetermined due to a dearth of knowledge on this topic.
Methods: In this paper, we present a clinicopathologic analysis of patients at our institution with this entity and 
compare them to age-matched controls with purely invasive ductal carcinoma (IDC) and historical data from patients 
with purely lobular carcinoma and also stain-available tumor specimens for E-cadherin. We have obtained 100 cases of 
ductal and 50 cases of mixed ductal/lobular breast carcinoma.
Results: Clinically, the behavior of mixed ductal/lobular tumors seemed to demonstrate some important differences 
from their ductal counterparts, particularly a lower rate of metastatic spread but with a much higher rate of second 
primary breast cancers.
Conclusions: Our data suggests that mixed ductal/lobular carcinomas are a distinct clinicopathologic entity 
incorporating some features of both lobular and ductal carcinomas and representing a pleomorphic variant of IDC.
Background
Infiltrating ductal carcinoma is the most common type of
invasive breast cancer, accounting for 65% to 80% of inva-
sive breast lesions[1,2]. Its characteristics have been well
described, including average age of onset, its rate of hor-
mone receptor and erbB2 positivity, frequency of nodal
involvement, rates of metastatic spread, and overall sur-
vival[3]. Historically, invasive lobular carcinomas (ILC)
represented the second most common subtype of mam-
mary neoplasia, accounting for about 5% to 10% of the
disease[4]. The clinical behavior of ILC has been known
to be different since its recognition as a distinct clinico-
pathologic entity[5]. Lobular carcinomas that are more
frequently hormone-receptor positive[6] display a higher
incidence of synchronous, contralateral primary
tumors[7], more frequently present with multicentric dis-
ease[8], and metastasize to distinct sites such as the
meninges, serosa, and retroperitoneum[9]. Given the dif-
ference in behavior between the two subtypes and the
unique behavior of the ILC, the initial diagnostic workup
has often involved the use of bilateral breast MRI to
assess the state of the contralateral breast. The molecular
characterization of breast cancer has substantially
advanced with the categorization of mammary carcino-
mas into distinct molecular subtypes[10], and we now
recognize the behavior patterns of breast carcinomas
based on the molecular signatures that they bear[11].
However, this methodology has not yet become routine
clinical practice. Fisher et al[12]. characterized over 1000
mammary carcinomas and recognized that the histologic
subtypes could be mixed. They characterized approxi-
mately one-third of the lesions as invasive ductal carci-
noma with one or more combined features. Slightly more
than half of the combined tumors were IDC with a tubu-
lar component, and combinations with lobular carcinoma
were detected in 6% of cases. It has also been seen that
prognosis and survival of invasive breast carcinoma
depends on the histology of the tumor[13,14].
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More recently, with the advent of immunohistochemis-
try, it has been realized that one mixed histologic subtype
of breast cancer, tubulolobular carcinoma of the breast,
first described in 1977 by Fisher et al. represent a pleo-
morphic variant of ductal carcinoma. Tubulocarcinomas
of the breast have classic grade I cytologic features and
intimately mixed tubular and linear architecture[15]. The
overall infiltrative pattern is that of lobular carcinoma,
but the tumors are E-cadherin positive. Esposito et al.
studied the clinical behavior of these tumors and con-
cluded that the behavior of these tumors parallel their
hybrid histology[16]. As E-cadherin was not lost in this
tumor histology, the authors concluded that "It may thus
be better termed 'ductal carcinoma, tubulolobular sub-
type', or 'ductal carcinoma with a tubulolobular pattern".
To date, the clinical presentation and prognosis of
mixed ductal/lobular mammary carcinomas has not been
well studied, and so little is known about the outcome of
this entity. There is a trend of increased (about 2-fold
increase) incidence of invasive ductal-lobular breast car-
cinoma from 1987 through 1999 in European studies, and
Bharat et al.[17] describe an incidence of 6% in their US
series[2,14]. To date, the best large study comes from Sas-
tre-Garau et al[4]. They studied 11,036 patients with non-
metastatic breast cancer during the 1981-1991 period
who were treated at the Institut Curie and prospectively
registered in the Breast Cancer database. Among these
patients, 726 cases corresponded to ILC, including the
classical form and its histological variants, and 249 cases
were classified as mixed ductal/lobular carcinoma. These
two groups of ILC and mixed ductal/lobular carcinomaw-
ere compared with the group of 10,061 cases, mostly of
the invasive ductal type (91% of cases), observed during
the same period. The focus of the study was the compari-
son of ductal carcinomas to lobular carcinomas and pre-
dated the era of MRI imaging of the breast. Thus, best
management practices remain undetermined due to a
dearth of knowledge on this topic. In this paper, we pres-
ent a clinicopathologic analysis of patients at our institu-
tion with this entity and compare them to age matched
controls with purely invasive ductal carcinoma and his-
torical data from patients with purely lobular carcinoma.
We also perform E-cadherin staining to determine if this
entity is best considered a variant of pleomorhic ductal
carcinoma or a true lobular carcinoma.
Methods
The study is a retrospective chart review of patients with
invasive ductal and mixed ductal/lobular breast cancers
diagnosed between 1990 and 1997. We obtained all cases
(50) of mixed ductal/lobular breast carcinoma during that
time period and matched them to 100 cases of IDC dur-
ing the same time period. The cases of IDC were matched
to the mixed ductal/lobular cases by both age and year of
diagnosis to within one year. The data was obtained from
the Cancer Registry at St. John's Hospital in Springfield,
IL. Surgical pathology specimens of mixed ductal/lobular
carcinoma were reviewed, and the percentage of lobular
carcinoma was estimated as a percentage of the entire
slide. The mixed ductal/lobular histology represents
tumors in which "the ductal not otherwise specified
(NOS) pattern comprises between 10% and 49% of the
tumor, the rest being of a recognized lobular type" as
defined by the WHO (Classification of tumours. Pathol-
ogy and Genetics. Tumours of the breast and female gen-
ital organs. IARC Press, Lyon 2003). All slides were
reviewed to generate a composite average for each case.
Demographics and patient follow-up were obtained from
the Cancer Registry at St. John's Hospital Cancer Insti-
tute. The variables evaluated include the patient's age at
diagnosis, year of diagnosis, pathology, percentage of lob-
ular and ductal in mixed carcinoma, type of surgery,
tumor size, TNM stage, axillary lymph node involvement,
adjuvant or neoadjuvant chemotherapy if given, radia-
tion, multiple breast cancers, local and distant recur-
rences, overall survival, and disease-free survival. Overall
survival, disease-free survival, and local recurrence were
directly calculated from the data, and the association of
clinical and pathologic variables was performed using
Cox proportional hazards regression analysis.
Additionally, a list of all the patients who had MRI of
the breast between years 2004 to 2007 was obtained from
the Radiology Department at St. John's Hospital. After
reviewing all the patients from the study group which
included 100 cases of invasive ductal and 50 cases of
mixed ductal/lobular pathology, we determined that a
total of 23 patients had MRI of the breast. On further
review of these pathology cases, there were 12 patients
with mixed ductal/lobular carcinoma who had MRI of the
breast. We then compared this group to 12 age-matched
control patients with a diagnosis of IDC who had also
undergone breast MRI at the time of initial diagnosis.
Patients in the ductal group were additionally matched
for the year of diagnosis to the mixed ductal/lobular his-
tology group to within one year. We reviewed the MRI
results of these cases and determined the rate of synchro-
nous contralateral breast cancers in both groups and then
performed a test of two proportions to determine if the
rate of synchronous contralateral tumors significantly dif-
fered.
E-cadherin staining was done on the 7 cases of mixed
ductal/lobular carcinomas as tissue blocks were available
for these cases. Methods have been previously
described[18-25]. Briefly, tissue was fixed in formalin, cut
into 4 μm sections, dried overnight, and deparaffinized.
Sections were rehydrated and underwent heat-induced
epitope retrieval. Sections were stained using a Ventana
Medical Systems (Tucson, AZ) automated system at 37°CSuryadevara et al. World Journal of Surgical Oncology 2010, 8:51
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for 32 minutes, followed by rinsing and cover-slipping.
Immunohistochemistry was considered positive if stain-
ing was present above background levels. Known nega-
tive and positive controls were run with the samples.
Statistical analysis was performed on the data from
both sets of patients. Logistic regression analysis using
SPSS software was performed by holding the occurrence
of a second primary breast cancer as a regression variable
while the age at diagnosis, pathologic tumor grade, tumor
size, and TNM stage were set as predictor variables. Cox
regression analysis was further performed on the data set
to determine if histology impacted overall survival or dis-
ease-free survival.
Results
Patient Demographics and Clinical Findings
All patients were female. Patients with mixed ductal/lob-
ular tumors ranged from ages 32 to 90, with an average
age of 62.28 years. Patients ranged in stages from I to IV.
The majority of patients were stage I, with a percentage of
50% (25/50) presenting at this early stage. Stage II
patients occurred at a frequency of 38% (19/50 cases),
while stage III (3/50) and stage IV (2/50) comprised of 6%
of cases and 4% of cases, respectively. Our control group
of IDCs was comprised of 100 age-matched cases. The
ages ranged from 31 to 90, with an average age of 59.07
years. The frequency of the various stages was stage I
(48%), stage II (35%), stage III (15%), and stage IV (1%).
Further patient characteristics are outlined in Table 1.
Pathologically, 14% of the tumors in the mixed ductal/
lobular group were grade I, 52% were grade II, 24% were
grade III, and 10% were listed with an unknown grade. In
the group of patients with invasive ductal carcinoma, 16%
of patients had grade I tumors, 43% had grade II tumors,
30% had grade III tumors and 11% had an unknown
grade. The average size of the primary tumors in the
mixed ductal/lobular group was 22.1 mm with a range in
size from 5 mm to 50 mm. In the ductal group, the aver-
age tumor size was 19.4 mm, with a range in size from 7
mm to 55 mm. This variable did differ significantly
between the two groups when analyzed by ANOVA (p =
0.022). Axillary lymph nodes were involved in 26% of
mixed ductal/lobular cases and 24% of ductal cases,
respectively. Purely ductal carcinomas were 67% ER posi-
tive, 18% ER unknown, and 15% ER negative. They were
52% PR positive, 20% unknown, and 28% PR negative.
Mixed ductal/lobular carcinomas were 74% ER positive,
10% ER unknown, and 16% ER negative. Mixed ductal/
lobular carcinomas were 48% PR positive, 40% PR nega-
tive, and 12% PR unknown. Pathologic characteristics are
outlined in Table 2.
On review of the 7 available cases of mixed ductal/lobu-
lar carcinoma pathology, the average percentage of ductal
carcinoma was 54.57% and the average percentage of lob-
ular carcinoma was 45.28%. The individual percentage of
lobular and ductal histology is listed for each case in
Table 3. Figures 1 and 2 illustrate a case of mixed ductal/
lobular histology, while Figures 3 and 4 illustrate the E-
cadherin staining on that specimen, confirming E-cad-
herin presence in the ductal and lobular component of
the tumor. Although the E-cadherin staining is weaker in
the lobular regions of the tumor, it is nonetheless present.
Overall, 90% (6/7) of the cases displayed E-cadherin posi-
tivity.
Post-surgical clinical treatment was subdivided into
chemotherapy, radiation therapy, and hormonal therapy.
Twenty-eight percent of the mixed ductal/lobular tumor
patients and 30% of the ductal patients received chemo-
therapy. In the mixed ductal/lobular group receiving che-
motherapy, 15.4% patients received doxorubicin, 30.8%
received doxorubicin/cyclophosphamide, 38.4% received
cyclophosphamide/methotrexate/5-FU, 7.7% received 5-
FU/leucovorin/methotrexate, and 7.7% received metho-
trexate. In the invasive ductal group receiving chemo-
therapy, 3.7% received 5-FU, 11% received doxorubicin/
cyclophosphamide, 26% received cyclophosphamide/
doxorubicin/5-FU, 55.6% received cyclophosphamide/5-
FU/methotrexate, and 3.7% received 5-FU/leucovorin/
methotrexate. Thirty-two percent of the mixed ductal/
lobular tumor patients and 31% of the IDC patients
received radiation. Radiation consisted of 5040 cGy in 28
treatment fractions given to the whole breast followed by
a 1000 cGy boost to the tumor in post-lumpectomy
patients. Post-mastectomy patients requiring radiation
received 5040 cGy in 28 treatment fraction to the
involved chest wall. Hormonal therapy was given to 36%
of patients in the mixed ductal/lobular histology group
and 35% of patients in the purely ductal histology group.
Virtually, all patients treated with hormonal therapy
received tamoxifen in either group.
Clinical Follow-up
Clinical follow-up was available for all patients and
ranged from 10 to 17 years. In the mixed ductal/lobular
group, the disease-free survival rate currently stands at
42% (21/50). Overall survival stands at 46%. Another 38%
(19/50) patients have expired without any evidence of
recurrence. Overall survival for this group averaged 12.2
years with a range of 10 to 17 years. Disease-free survival
was an average of 8 years with a range of 0 to 15.25 years.
Three patients were deemed "never disease-free", consti-
tuted 6% of the population, and have expired. An addi-
tional 6% (3/50) of patients had local or regional relapse
of their tumor, and one of these patients has been suc-
cessfully treated and remains disease-free. The rate of
distant metastatic spread was 8% (4/50), and sites of
metastasis included bone (2 patients) and lung (2
patients).Suryadevara et al. World Journal of Surgical Oncology 2010, 8:51
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In the group of patients with ductal histology, the dis-
ease-free survival rate remains at 36%. Overall survival is
39%. Another 32% have expired without any evidence of
recurrence. Eight percent of patients had a local or
regional recurrence, 2% of patients had a recurrence that
was not further specified, 3% were never disease-free, and
19% of patients developed distant metastatic spread.
Liver metastases were present in 3% of patients. Lung
metastases developed in 5% of patients. Bone metastases
developed in another 11% of patients. Overall survival for
the ductal group was 9.23 years with a range of 1 month
to 17.8 years. Disease-free survival ranged from 0 months
to 16.9 years with an average of 8.42 years. Interestingly,
30% (15/50) of the patients with mixed ductal/lobular his-
tology breast cancer and 11% of the patients with ductal
histology had a second primary breast cancer. There were
12 patients with mixed ductal/lobular breast carcinoma
who had MRI of the breast, and 2 out of 12 patients
(16.66%) had suspicious contralateral lesions. On review
of the pathology, one case had carcinoma in-situ  and
other case had benign, fibrocystic changes in the contra-
lateral breast. Thus, there was no case of contralateral
invasive breast cancer. The 12 cases of invasive ductal
breast carcinoma also had no contralateral breast cancer
on review of the radiology results. One patient did have a
benign fibroadenoma, but there were no cases of in-situ
or invasive malignancy. Patient characteristics for these
two groups are listed in Table 4.
Statistical analysis was performed on the data from
both sets of patients. Logistic regression analysis using
SPSS software was performed. Holding the occurrence of
a second primary breast cancer as a regression variable,
age at diagnosis, pathologic tumor grade, tumor size, and
TNM stage were not significant prognostic factors with β
significance values of 0.447, 0.158, 0.490, and 0.424,
respectively. However, the β value for tumor histology did
achieve a significance of 0.05 and appears to be a strong
predictor of secondary breast cancer development. The
odds ratio of developing a second primary breast cancer
was 7.95 with the mixed ductal/lobular histology using a
Chi-square statistical model. Cox regression analysis was
performed on the data set to determine if histology
impacted overall survival or disease-free survival.
Although TNM stage and tumor grade were both sig-
nificant factors impacting overall survival and disease-
free survival, histology was not a significant variable for
Table 1: Clinical characteristics
Clinical Characteristics Invasive Ductal Carcinoma Mixed Ductal/Lobular Carcinoma
Number of Cases 100 50
Age-Range (Year) 31 to 89 32 to 90
Age-Average (Year) 59.07 62.28
Stage I 48 (48%) 25 (50%)
State II 35 (35%) 19 (38%)
Stage III 15 (15%) 3 (6%)
Stage IV 1 (1%) 2 (4%)
Stage Unknown 1 (1%) 1 (2%)
Modified Radical Mastectomy 67 (67%) 31 (62%)
Partial Mastectomy 26 (26%) 14 (28%)
Simple Mastectomy 5 (5%) 5 (10%)
Unknown Specific Surgery 2 (2%) 0
Clinical characteristics of all the cases of invasive ductal carcinoma and mixed ductal/lobular carcinoma are summarizedSuryadevara et al. World Journal of Surgical Oncology 2010, 8:51
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both of these parameters, with a significance level of
0.728 with respect to overall survival and a significance
level of 0.721 with respect to disease-free survival. Figure
5 depicts the overall survival curve for the two groups
while Figure 6 depicts the disease-free survival for the
two groups.
Discussions
Analysis of our cases of mixed ductal/lobular histology
has yielded several facts. Tumor size was larger in our
mixed ductal/lobular histology patients, which may
account for the higher rate of mastectomies. Tumor grade
did not substantially differ between the ductal and mixed
ductal/lobular histologies. Mixed ductal/lobular histol-
ogy tumors were not significantly more likely to be ER
negative and PR negative. Treatment did not also signifi-
cantly differ between the 2 groups, with both groups
receiving chemotherapy, radiation, and hormonal therapy
at similar rates. Paired sample t-testing revealed no statis-
tically significant difference between the 2 groups of
patients (mixed ductal/lobular versus ductal histology)
with regard to tumor grade or TNM stage.
Although the literature on this topic is scant, our data is
in agreement with the published report of Sastre-Garau
et al[4], who included 249 cases of mixed ductal/lobular
histology tumors in their review. They noted a 10-year
c o n t r a l a t e r a l  d i s e a s e - f r e e  r a t e  o f  9 0 %  i n  d u c t a l  b r e a s t
cancers and 90% in lobular cancers while mixed ductal/
lobular histology tumors had a significantly diminished
rate of 80%. As in our series, overall survival among the
two subtypes did not significantly vary. In our more
recently diagnosed cohort of patients, for whom breast
MRI had become available, none of our patients had a
contralateral synchronous invasive breast tumor and only
one patient had a breast lesion (in the mixed ductal/lobu-
lar tumor group) which was pathologically a case of duc-
Table 2: Pathological features
Pathological Features Invasive Ductal Carcinoma Mixed Ductal/Lobular Carcinoma
Number of Cases 100 50
Grade I 16 (16%) 7 (14%)
Grade II 43 (43%) 26 (52%)
Grade III 30 (30%) 12 (24%)
Grade Unknown 11 (11%) 5 (10%)
Tumor Size-Range 7-55 mm 5-50 mm
Tumor Size-Average 19.4 mm 22.1 mm
Axillary Lymph Nodes 24 (24%) 13 (26%)
ER Positive 67 (67%) 37 (74%)
ER Negative 15 (15%) 8 (16%)
ER Unknown 18 (18%) 5 (10%)
PR Positive 52 (52%) 24 (48%)
PR Negative 28 (28%) 20 (40%)
PR Unknown 20 (20%) 6 (12%)
Pathological features of all cases of invasive ductal carcinoma and mixed ductal/lobular carcinoma are summarized above. These include 
grade of tumor, tumor size-range and average, positivity of axillary lymph nodes and ER/PR status of the tumor.Suryadevara et al. World Journal of Surgical Oncology 2010, 8:51
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tal carcinoma in-situ  (DCIS). One patient in the IDC
group had a benign fiboadenoma in the contralateral
breast. Thus, there was no significant difference between
the two groups of patients (mixed ductal/lobular histol-
ogy and purely ductal carcinoma) with regard to synchro-
nous contralateral breast tumors.
Arpino et al.[26] recently published their institutional
experience with ILC. The median age of their patients
with ILC was 64.6. The proportion of ER-positive tumors
was 92.7%, and PR was expressed in 67.4% of ILCs. The
pattern of metastatic dissemination in ILC was also dif-
ferent. ILC was three times more likely to metastasize to
the peritoneum, gastrointestinal tract, and ovaries (6.7%
versus 1.8%). Information on contralateral breast tumors
was also available on the subset of 2,855 patients in whom
sites of breast cancer distant from the primary could be
assessed. Contralateral breast cancers in this group were
more frequent among those with ILC (20.9%) than among
those with IDC (11.2%). No difference in overall or dis-
ease-free survival was noted between ILC and IDC.
Bharat et al. recently compared the outcomes for IDC,
ILC, and mixed ductal/lobular histology tumors at their
institution[17]. Patients with mixed ductal/lobular histol-
ogy tumors and ILC were more likely to have low grade
and hormone-receptor positive tumors, but also more
likely to have stage III disease. The 10-year long-term
survival, however, was better in patients with ILC (69%)
and mixed ductal/lobular histology tumors (68%) than in
patients with IDC (61%).
Figure 1 H&E of a mixed ductal/lobular tumor. 200× magnification 
of an H/E stained section of mixed ductal/lobular histology tumor. 
Ductal histology is noted.
Figure 2 H&E of a mixed ductal/lobular tumor. 200× magnification 
of an H/E stained section of mixed ductal/lobular histology tumor. 
Lobular histology is noted.
Figure 3 E-cadherin immunostaining of the ductal components 
of the tumor. E-cadherin staining on the same specimen displays the 
presence of E-cadherin in the ductal areas of the tumor.
Figure 4 E-cadherin immunostaining of the lobular components 
of the tumor. E-cadherin staining on the same specimen displays the 
presence of E-cadherin in the lobular component of the tumor, sug-
gesting that this mixed ductal/lobular tumor is indeed a variant of 
pleomorphic ductal carcinoma.Suryadevara et al. World Journal of Surgical Oncology 2010, 8:51
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Clinically, in our series, the behavior of mixed ductal/
lobular tumors seemed to demonstrate some important
differences from their ductal counterparts. The rate of
dista n t  m etasta t ic s pr ea d was  m uc h l owe r  a t  8% c om -
pared to a rate of 19% for the ductal tumors. The sites of
spread were the lungs and bones, and mimicked the pat-
t e rn  o f  m e t as t ase s  b y  IDC.  T h e  r a t e s  o f  l oca l / r e gi o n a l
relapse were identical between the pure ductal and mixed
ductal/lobular histology tumors, with both histologies
demonstrating a 6% rate. However, the rate of second pri-
mary breast cancers was much higher at 30% compared
with a rate of 11% with ductal histology. The rates of hor-
mone-receptor positivity and age of onset were similar
between the mixed ductal/lobular histology and purely
ductal histology and did not differ from historically cited
data in the literature[26]. However, unlike ILC, the rate of
synchronous contralateral breast cancer (0%) was much
lower, mimicking the ductal histology. This value was
highly significant and suggests a different pattern of
recurrence and different tumor biology. The literature
also indicates that the mixed ductal/lobular histology, like
I L C ,  i s  m o r e  l i k e l y  t o  b e  a s s o c i a t e d  w i t h  h o r m o n e
Table 3: Pathology slides
Case Percentage of Ductal Carcinoma Percentage of Lobular Carcinoma
12 2 7 7
27 0 3 0
35 0 5 0
46 0 4 0
55 0 5 0
68 0 2 0
75 0 5 0
Average 54.57 45.28
All the slides available (7 cases) on mixed ductal/lobular cases were reviewed under light microscopy and percentage of ductal and lobular 
carcinoma on each slide was estimated and summarized.
Table 4: Clinical characteristics and MRI findings
Clinical Characteristics Invasive Ductal Carcinoma Mixed Ductal/Lobular Carcinoma
Number of Cases 12 12
Age-Range (Year) 37 to 78 33 to 84
Age-Average (Year) 53.2 54.5
Suspicious MRI findings 8% (1/12) 16% (2/12)
Invasive disease in contralateral breast 0% 0%
In situ disease in contralateral breast 0% 8% (1/12)
Other pathology in contralateral breast 8% (1/12- fibroadenoma) 8% (1/12- fibrocystic changes)
Clinical characteristics and pathologic findings in 24 patients undergoing breast MRI are outlined.Suryadevara et al. World Journal of Surgical Oncology 2010, 8:51
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replacement therapy[27,28]. Reeves et al. conducted 3.6
million person-years of follow-up on over 1 million post-
menopausal women in the UK[28]. They found that the
largest relative risks in current users of hormone therapy
compared with never users of hormone therapy were
seen for lobular (relative risk 2.25, 95% CI 2.00--2.52),
mixed ductal/lobular (2.13, 1.68--2.70), and tubular can-
cers (2.66, 2.16--3.28). The only subtype that did not rise
in incidence in their study was medullary carcinoma.
Reeves et al. followed up with an analysis of reproductive
factors and histologic subtype in their cohort of patients
and interestingly found that "for most of the reproductive
factors considered, the relative risks for mixed ductal/
lobular carcinoma were intermediate between those
found for ductal and lobular cancer[29]."
Our immunohistochemistry data suggests that mixed
ductal/lobular carcinoma is another pleomorphic variant
of IDC as 90% of the cases stained positively for E-cad-
herin. However, more tissue will be required to statisti-
cally confirm this trend. Of the available blocks, only one
case did not stain for E-cadherin and may truly represent
a lobular carcinoma. Wheeler et al.[30] have character-
ized tubulocarcinomas of the breast. Although our
tumors did mostly stain for E-cadherin as well, we do not
think our tumors represent tubulolobular carcinomas as
"this histologic pattern is distinct from other mixed duc-
tal/lobular carcinomas in which the invasive components
are often separate and the tubular component lacks a lob-
ular growth pattern." Additionally, morphologically, our
cases did not meet the diagnostic criteria for tubulolobu-
lar carcinoma due to a lack of any tubular elements.
Conclusions
Our data suggests that mixed ductal/lobular carcinomas
are a distinct clinicopathologic entity incorporating some
features of both lobular and ductal carcinomas and
immunohistochemically may represent another variant of
IDC. Scant information has been available to date on this
entity. Based on our series of patients, it appears that rou-
tine breast MRI to screen the contralateral breast for an
occult mammary malignancy is not warranted. However,
clinical vigilance for the emergence of a second primary
breast malignancy is mandated given the excessive rate of
a second primary breast tumor.
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Figure 5 Overall Survival. Kaplan-Meier plot of overall survival of pa-
tients with mixed ductal/lobular histology tumors and patients with 
purely invasive ductal carcinomas reveals no significant difference be-
tween the two groups.
Figure 6 Disease-Free Survival. Kaplan-Meier plot of disease-free 
survival of patients with mixed ductal/lobular histology tumors and 
patients with purely invasive ductal carcinomas reveals no significant 
between the two groups as well.Suryadevara et al. World Journal of Surgical Oncology 2010, 8:51
http://www.wjso.com/content/8/1/51
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